Introduction/objective: Apremilast, PDE4 competitive inhibitor, has been recently introduced in the treatment of adult psoriatic arthritis (PsA) patients, but only preliminary data are available on imaging evaluation. Thus, we evaluated the response to apremilast in PsA patients by ultrasonographic (US) assessment. Methods: Thirty-four patients (M/F 7/27; median age 61 years, IQR 15; median disease duration 10 years, IQR 13) treated for polyarticular involvement were longitudinally evaluated. All the patients were assessed at baseline (T0), and after 6 (T1), 12 (T2), and 24 weeks (T3) by DAS28, CDAI, SDAI, and DAPSA. At the same time-points, US assessment was performed in 22 sites (wrists, MCPs, PIPs): synovial effusion/hypertrophy and power Doppler were scored with a semi-quantitative scale (0–3). A total score, corresponding to patient’s inflammatory status, was obtained by their sum (0–198). We assessed also the presence of tenosynovitis of flexor tendons of hands’ fingers bilaterally, registering the number of involved tendons (US-tenosynovitis score 0–10). Results: We found a significant reduction in the US inflammatory score values after 6 weeks (T0, median 15 (IQR 11.2); T1, 6 (10.0); P = 0.0002), confirmed at T2 (4.0 (4.0), P = 0.0002) and T3 (4.0 (6.0); P = 0.0003). Finally, US-detected tenosynovitis was observed in 44.1% of patients: a significant improvement in tenosynovitis score was identified at 6 weeks (T0, median 4 (IQR 4); T1, 1 (2); P < 0.0001) and maintained at T2 (0 (IQR 1); P < 0.0001) and T3 ((IQR 1.25); P < 0.0001). Conclusions: Apremilast is able to induce an early and sustained improvement of ultrasonographic inflammatory status at articular and peri-articular level.

Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study / Ceccarelli, F.; Lucchetti, R.; Perricone, C.; Spinelli, F. R.; Cipriano, E.; Truglia, S.; Miranda, F.; Riccieri, V.; Di Franco, M.; Scrivo, R.; Alessandri, C.; Valesini, G.; Conti, F.. - In: CLINICAL RHEUMATOLOGY. - ISSN 0770-3198. - 38:11(2019), pp. 3145-3151. [10.1007/s10067-019-04674-3]

Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study

Ceccarelli F.
;
Lucchetti R.;Spinelli F. R.;Cipriano E.;Truglia S.;Riccieri V.;Di Franco M.;Scrivo R.;Alessandri C.;Valesini G.;Conti F.
2019

Abstract

Introduction/objective: Apremilast, PDE4 competitive inhibitor, has been recently introduced in the treatment of adult psoriatic arthritis (PsA) patients, but only preliminary data are available on imaging evaluation. Thus, we evaluated the response to apremilast in PsA patients by ultrasonographic (US) assessment. Methods: Thirty-four patients (M/F 7/27; median age 61 years, IQR 15; median disease duration 10 years, IQR 13) treated for polyarticular involvement were longitudinally evaluated. All the patients were assessed at baseline (T0), and after 6 (T1), 12 (T2), and 24 weeks (T3) by DAS28, CDAI, SDAI, and DAPSA. At the same time-points, US assessment was performed in 22 sites (wrists, MCPs, PIPs): synovial effusion/hypertrophy and power Doppler were scored with a semi-quantitative scale (0–3). A total score, corresponding to patient’s inflammatory status, was obtained by their sum (0–198). We assessed also the presence of tenosynovitis of flexor tendons of hands’ fingers bilaterally, registering the number of involved tendons (US-tenosynovitis score 0–10). Results: We found a significant reduction in the US inflammatory score values after 6 weeks (T0, median 15 (IQR 11.2); T1, 6 (10.0); P = 0.0002), confirmed at T2 (4.0 (4.0), P = 0.0002) and T3 (4.0 (6.0); P = 0.0003). Finally, US-detected tenosynovitis was observed in 44.1% of patients: a significant improvement in tenosynovitis score was identified at 6 weeks (T0, median 4 (IQR 4); T1, 1 (2); P < 0.0001) and maintained at T2 (0 (IQR 1); P < 0.0001) and T3 ((IQR 1.25); P < 0.0001). Conclusions: Apremilast is able to induce an early and sustained improvement of ultrasonographic inflammatory status at articular and peri-articular level.
2019
Apremilast; Joint inflammation; Psoriatic arthritis; Treatment response; Ultrasonographic assessment
01 Pubblicazione su rivista::01a Articolo in rivista
Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study / Ceccarelli, F.; Lucchetti, R.; Perricone, C.; Spinelli, F. R.; Cipriano, E.; Truglia, S.; Miranda, F.; Riccieri, V.; Di Franco, M.; Scrivo, R.; Alessandri, C.; Valesini, G.; Conti, F.. - In: CLINICAL RHEUMATOLOGY. - ISSN 0770-3198. - 38:11(2019), pp. 3145-3151. [10.1007/s10067-019-04674-3]
File allegati a questo prodotto
File Dimensione Formato  
Ceccarelli_Musculoskeletal_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 728.33 kB
Formato Adobe PDF
728.33 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1341097
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact